Real‐World Progression Patterns and Potential Prognostic Factors for Trastuzumab Deruxtecan‐Related Interstitial Lung Disease in Japanese Patients With Breast or Gastric Cancer
Cancer Medicine · 2026-11 · 15 (11)
DOI: 10.1002/cam4.72489 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Cancer Medicine, online erschienen am 09.11.2026. Verfasst von Shinichi Sasaki und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Juntendo University Urayasu Hospital, Chiba, Japan. Hauptthemen laut MEDLINE: Breast Neoplasms, Lung Diseases, Interstitial, Stomach Neoplasms, Trastuzumab. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Daiichi Sankyo Company.
Abstract (Originalsprache)
Background
Interstitial lung disease (ILD)/pneumonitis is a safety concern with trastuzumab deruxtecan (T‐DXd). We characterized post‐onset changes in ILD severity and imaging patterns, and explored potential prognostic factors for fatal T‐DXd‐related ILD in Japanese patients with breast or gastric cancer.
Methods
This post hoc analysis included 381 independently adjudicated T‐DXd‐related ILD cases from two Japanese all‐patient post‐marketing surveillance studies. We described transitions from onset to worst Common Terminology Criteria for Adverse Events grade and imaging pattern changes. Exploratory tumor type‐stratified Cox proportional hazards models were used to assess factors associated with time to fatal (Grade 5) ILD. The variable with the highest hazard ratio (HR) and each of the remaining significant univariate factors ( p < 0.05 or a 95% confidence interval excluding 1) meeting the criteria were included in two‐covariate multivariable models.
Results
At ILD onset, 60.1% of patients had Grade 1 ILD. Overall, 30 of the 381 adjudicated ILD cases (7.9%) progressed to fatal Grade 5, initially presenting with Grade 1 ( n = 9), 2 ( n = 5), or 3 ( n = 16); time to death was 3–173 days. Of 24 cases with imaging pattern changes, 14 transitioned from nondiffuse alveolar damage (non‐DAD) to DAD (10 were fatal). Abnormal C‐reactive protein (CRP) at onset had the highest HR in univariate analyses. In separate CRP‐adjusted two‐covariate multivariable models, preexisting ILD and several onset factors (dyspnea; abnormal SpO 2 /lactate dehydrogenase/Krebs von den Lungen‐6; pleural/cardiac effusion; DAD pattern; traction bronchiectasis) were associated with fatal ILD. An organizing pneumonia pattern was associated with a lower hazard.
Conclusions
T‐DXd‐related ILD may progress rapidly to fatal outcomes, even from low‐grade or non‐DAD presentations, and several onset factors (e.g., elevated CRP, decreased SpO 2 , and DAD pattern) were associated with fatal ILD outcomes. These findings are exploratory and should not be used to determine whether to initiate or withhold corticosteroids. Guideline‐concordant ILD management remains essential regardless of these factors, while their potential role in identifying patients requiring closer monitoring warrants further validation. Trial Registration The breast cancer and the gastric cancer surveys were registered at the Japan Registry of Clinical Trials ( https://jrct.mhlw.go.jp/en‐top ) under the identifiers jRCT1080225197 and jRCT2001200001, respectively
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Juntendo University Urayasu Hospital, Chiba, Japan.
- Department of Diagnostic Radiology, Toranomon Hospital, Tokyo, Japan.
- Department of Respiratory Medicine, Kanagawa Cardiovascular & Respiratory Center, Yokohama, Japan.
- Midtown Clinic East, Tokyo, Japan.
- Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
- Division of Diagnostic Radiology, Shizuoka Cancer Center, Shizuoka, Japan.
ORCID-Profile: Shinichi Sasaki, Tomohisa Baba, Masahiko Kusumoto, Yutaka Fujiwara, Masahiro Endo, Terufumi Kato, Masafumi Sata, Yoshinao Sato, Hirotsugu Kenmotsu, Taiki Fukuda, Teppei Yamaguchi, Hiroshi Wakui, Haruki Kobayashi, Satoshi Ikeda, Motoyasu Kato, Toshimi Takano, Ken Kato, Akiko Takenaka, Koji Hirata, Wataru Hashimoto
Förderung
- Daiichi Sankyo Company
Zitieren
APA
Sasaki, S., Oikado, K., Baba, T., Kusumoto, M., Fujiwara, Y., Endo, M., Kato, T., Kurihara, Y., Saito, Y., Yagihashi, K., Sata, M., Sato, Y., Kenmotsu, H., Fukuda, T., Yamaguchi, T., Isshiki, S., Wakui, H., Kobayashi, H., Ikeda, S., …, & Kuwano, K. (2026). Real‐World Progression Patterns and Potential Prognostic Factors for Trastuzumab Deruxtecan‐Related Interstitial Lung Disease in Japanese Patients With Breast or Gastric Cancer. Cancer Medicine, 15(11). https://doi.org/10.1002/cam4.72489
Vancouver
Sasaki S, Oikado K, Baba T, Kusumoto M, Fujiwara Y, Endo M, et al. Real‐World Progression Patterns and Potential Prognostic Factors for Trastuzumab Deruxtecan‐Related Interstitial Lung Disease in Japanese Patients With Breast or Gastric Cancer. Cancer Medicine. 2026;15(11). doi:10.1002/cam4.72489
BibTeX
@article{Sasaki2026,
author = {Sasaki, Shinichi and Oikado, Katsunori and Baba, Tomohisa and Kusumoto, Masahiko and Fujiwara, Yutaka and Endo, Masahiro and Kato, Terufumi and Kurihara, Yasuyuki and Saito, Yoshinobu and Yagihashi, Kunihiro and Sata, Masafumi and Sato, Yoshinao and Kenmotsu, Hirotsugu and Fukuda, Taiki and Yamaguchi, Teppei and Isshiki, Saiko and Wakui, Hiroshi and Kobayashi, Haruki and Ikeda, Satoshi and Kato, Motoyasu and Yamaguchi, Ou and Takano, Toshimi and Kato, Ken and Takenaka, Akiko and Hirata, Koji and Hashimoto, Wataru and Kuwano, Kazuyoshi},
title = {Real‐World Progression Patterns and Potential Prognostic Factors for Trastuzumab Deruxtecan‐Related Interstitial Lung Disease in Japanese Patients With Breast or Gastric Cancer},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {11},
doi = {10.1002/cam4.72489}
}
EUVIMED